Elliott Spitzer walks away from prosecuting coporate crimes Sat, 25 Dec 2004 “After nearly three years of high-profile prosecutions of investment banks, mutual funds and insurance companies, Attorney General Eliot Spitzer of New York said yesterday that he is ready to cede those investigations to federal regulators.” Whatever Eliot Spitzer…
Doctors On the Take-Engaging in Vairous Dubious Activities for Cash / Stock Options Tue, 16 Aug 2005 A series of current articles in The Wall Street Journal, the Journal of the American Medical Association (JAMA), and the New York Times describe the many questionable non-medical income-producing activities that America¹s physicians…
Zolft pediatric study in JAMA challenged by peers – JAMA letters Fri, 9 Jan 2004 At the time that two manufacturers publicly acknowledged that their antidepressant drugs (Paxil / Seroxat and Effexor) were unsafe, and ineffective for children, the Journal of the American Medical Association (JAMA) published a clinical trial…
A Special Article By Curt D. Furberg, MD, PhD; Arthur A. Levin, MPH; Peter A. Gross, MD; Robyn S. Shapiro, JD; Brian L. Strom, MD, MPH
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Pharmaceutical industry corrupt practices are in evidence again, and again, and again.
Evidence of an association between violence and widely prescribed antidepressant drugs is the focus of this Infomail.
A study published in The Journal of the National Cancer Institute, found that advanced chemotherapy put patients at far greater
risks of harm than adverse effect reports from clinical trial data reveal.
Suicide rates fluctuate. Like the stock market their rise and fall is not due to a single decisive cause, but rather to a confluence of complex factors.
A Boston Globe report (below) focuses on three recent reports in the Journal of the American Medical Association (JAMA) by Harvard researchers who violated the journal’s disclosure policy by failing to disclose their financial ties to companies that had the most to gain from their purported findings.
The Times’ humorous profile of JAMA’s editor attempts to trivialize the threat to public health when journals fail to maintain the integrity of science-based medicine.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
